Waldenström's macroglobulinemia differential diagnosis: Difference between revisions
Jump to navigation
Jump to search
No edit summary |
No edit summary |
||
| Line 5: | Line 5: | ||
==Overview== | ==Overview== | ||
Waldenström macroglobulinemia must be differentiated from [[multiple myeloma]], [[chronic lymphocytic leukemia]]/[[small lymphocytic lymphoma]], [[b-cell prolymphocytic leukemia]], [[follicular lymphoma]], [[mantle cell lymphoma]], and marginal zone lymphoma. | Waldenström macroglobulinemia must be differentiated from [[multiple myeloma]], [[chronic lymphocytic leukemia]]/[[small lymphocytic lymphoma]], [[b-cell prolymphocytic leukemia]], [[follicular lymphoma]], [[mantle cell lymphoma]], and marginal zone lymphoma. | ||
==Differentiating Waldenström's Macroglobulinemia from other B Cell Lymphoid Neoplasms== | ==Differentiating Waldenström's Macroglobulinemia from other B Cell Lymphoid Neoplasms== | ||
| Line 26: | Line 26: | ||
:*Express CD138, CD38, CD79a, VS38c and CD56 (70%) | :*Express CD138, CD38, CD79a, VS38c and CD56 (70%) | ||
:*Presence of plasmacytic cell infiltration of bone marrow, osteolytic lesions, and [[renal insufficiency]] | :*Presence of plasmacytic cell infiltration of bone marrow, osteolytic lesions, and [[renal insufficiency]] | ||
:*Translocation involving chromosome 11 (t11;14)<ref name="UTD">{{cite journal |vauthors= | :*Translocation involving chromosome 11 (t11;14)<ref name="UTD">{{cite journal |vauthors=Pangalis GA, Kyrtsonis MC, Kontopidou FN, Vassilakopoulos TP, Siakantaris MP, Dimopoulou MN, Kittas C, Angelopoulou MK |title=Differential diagnosis of Waldenstrom's macroglobulinemia from other low-grade B-cell lymphoproliferative disorders |journal=Semin. Oncol. |volume=30 |issue=2 |pages=201–5 |year=2003 |pmid=12720136 |doi=10.1053/sonc.2003.50046 |url=}}</ref> | ||
*[[Mantle cell lymphoma]]: | *[[Mantle cell lymphoma]]: | ||
Revision as of 14:39, 31 October 2018
Editor-In-Chief: C. Michael Gibson, M.S., M.D. [1]Associate Editor(s)-in-Chief:
Mirdula Sharma, MBBS [2]Roukoz A. Karam, M.D.[3]
|
Waldenström's macroglobulinemia Microchapters |
|
Differentiating Waldenström's macroglobulinemia from other Diseases |
|---|
|
Diagnosis |
|
Treatment |
|
Case Studies |
|
Waldenström's macroglobulinemia differential diagnosis On the Web |
|
American Roentgen Ray Society Images of Waldenström's macroglobulinemia differential diagnosis |
|
FDA on Waldenström's macroglobulinemia differential diagnosis |
|
CDC on Waldenström's macroglobulinemia differential diagnosis |
|
Waldenström's macroglobulinemia differential diagnosis in the news |
|
Blogs on Waldenström's macroglobulinemia differential diagnosis |
|
Directions to Hospitals Treating Waldenström's macroglobulinemia |
|
Risk calculators and risk factors for Waldenström's macroglobulinemia differential diagnosis |
Overview
Waldenström macroglobulinemia must be differentiated from multiple myeloma, chronic lymphocytic leukemia/small lymphocytic lymphoma, b-cell prolymphocytic leukemia, follicular lymphoma, mantle cell lymphoma, and marginal zone lymphoma.
Differentiating Waldenström's Macroglobulinemia from other B Cell Lymphoid Neoplasms
Waldenström macroglobulinemia must be differentiated from other B cell lymphoid neoplasms including:
- Always express CD5
- Usually CD23 positive[1]
- Express CD138, CD38, CD79a, VS38c and CD56 (70%)
- Presence of plasmacytic cell infiltration of bone marrow, osteolytic lesions, and renal insufficiency
- Translocation involving chromosome 11 (t11;14)[6]
- Marginal zone lymphoma:
References
- ↑ Hallek M, Cheson BD, Catovsky D, Caligaris-Cappio F, Dighiero G, Döhner H, Hillmen P, Keating MJ, Montserrat E, Rai KR, Kipps TJ (2008). "Guidelines for the diagnosis and treatment of chronic lymphocytic leukemia: a report from the International Workshop on Chronic Lymphocytic Leukemia updating the National Cancer Institute-Working Group 1996 guidelines". Blood. 111 (12): 5446–56. doi:10.1182/blood-2007-06-093906. PMC 2972576. PMID 18216293.
- ↑ Del Giudice I, Davis Z, Matutes E, Osuji N, Parry-Jones N, Morilla A, Brito-Babapulle V, Oscier D, Catovsky D (2006). "IgVH genes mutation and usage, ZAP-70 and CD38 expression provide new insights on B-cell prolymphocytic leukemia (B-PLL)". Leukemia. 20 (7): 1231–7. doi:10.1038/sj.leu.2404238. PMID 16642047.
- ↑ Ravandi F, O'Brien S (2005). "Chronic lymphoid leukemias other than chronic lymphocytic leukemia: diagnosis and treatment". Mayo Clin. Proc. 80 (12): 1660–74. doi:10.4065/80.12.1660. PMID 16342661.
- ↑ Karube K, Guo Y, Suzumiya J, Sugita Y, Nomura Y, Yamamoto K, Shimizu K, Yoshida S, Komatani H, Takeshita M, Kikuchi M, Nakamura N, Takasu O, Arakawa F, Tagawa H, Seto M, Ohshima K (2007). "CD10-MUM1+ follicular lymphoma lacks BCL2 gene translocation and shows characteristic biologic and clinical features". Blood. 109 (7): 3076–9. doi:10.1182/blood-2006-09-045989. PMID 17138820.
- ↑ Anderson KC, Bates MP, Slaughenhoupt BL, Pinkus GS, Schlossman SF, Nadler LM (1984). "Expression of human B cell-associated antigens on leukemias and lymphomas: a model of human B cell differentiation". Blood. 63 (6): 1424–33. PMID 6609729.
- Bone marrow infiltration of small, cleaved cells that are usually paratrabecular
- ↑ Pangalis GA, Kyrtsonis MC, Kontopidou FN, Vassilakopoulos TP, Siakantaris MP, Dimopoulou MN, Kittas C, Angelopoulou MK (2003). "Differential diagnosis of Waldenstrom's macroglobulinemia from other low-grade B-cell lymphoproliferative disorders". Semin. Oncol. 30 (2): 201–5. doi:10.1053/sonc.2003.50046. PMID 12720136.
- ↑ Dorfman DM, Pinkus GS (1994). "Distinction between small lymphocytic and mantle cell lymphoma by immunoreactivity for CD23". Mod. Pathol. 7 (3): 326–31. PMID 8058704.
- ↑ DiRaimondo F, Albitar M, Huh Y, O'Brien S, Montillo M, Tedeschi A, Kantarjian H, Lerner S, Giustolisi R, Keating M (2002). "The clinical and diagnostic relevance of CD23 expression in the chronic lymphoproliferative disease". Cancer. 94 (6): 1721–30. PMID 11920534.
- ↑ Harris NL, Jaffe ES, Diebold J, Flandrin G, Muller-Hermelink HK, Vardiman J, Lister TA, Bloomfield CD (1999). "World Health Organization classification of neoplastic diseases of the hematopoietic and lymphoid tissues: report of the Clinical Advisory Committee meeting-Airlie House, Virginia, November 1997". J. Clin. Oncol. 17 (12): 3835–49. PMID 10577857.
- ↑ Harris NL, Jaffe ES, Stein H, Banks PM, Chan JK, Cleary ML, Delsol G, De Wolf-Peeters C, Falini B, Gatter KC (1994). "A revised European-American classification of lymphoid neoplasms: a proposal from the International Lymphoma Study Group". Blood. 84 (5): 1361–92. PMID 8068936.